BR0313151A - métodos e reagentes que se relacionam à inflamação e à apoptose - Google Patents

métodos e reagentes que se relacionam à inflamação e à apoptose

Info

Publication number
BR0313151A
BR0313151A BRPI0313151-3A BR0313151A BR0313151A BR 0313151 A BR0313151 A BR 0313151A BR 0313151 A BR0313151 A BR 0313151A BR 0313151 A BR0313151 A BR 0313151A
Authority
BR
Brazil
Prior art keywords
inflammation
apoptosis
methods
reagents
relate
Prior art date
Application number
BRPI0313151-3A
Other languages
English (en)
Inventor
Jun Kuai
Lih-Ling Lin
Joseph L Wooters
Elliott Nickbarg
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0313151A publication Critical patent/BR0313151A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

MéTODO E REAGENTE QUE SE RELACIONAM à INFLAMAçãO E à APOPTOSE A presente invenção relaciona-se, entre outras modalidades, aos complexos protéicos que incluem o fator de necrose tumoral alfa (TNF-<244>) e ou o recptor de fator de necrose tumoral alfa (TNFR). De preferência, os compelxos compreendem pelo menos um polipeptídeo selecionado a partir do grupo consistindo em: cinase ativadora de NF-kB (NAK), RasGAP3, TRCP1, e TRCP2. A presente invenção adicionalmente proporciona ensaios de identificação de um composto para modular a estabilidade e a atividade do complexo. Também proporcionados são os métodos de modular a apoptose e a inflamação, bem como tratar as doenças relacionadas ao TNF-<244>.
BRPI0313151-3A 2002-08-01 2003-08-01 métodos e reagentes que se relacionam à inflamação e à apoptose BR0313151A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40041002P 2002-08-01 2002-08-01
PCT/US2003/024340 WO2004012673A2 (en) 2002-08-01 2003-08-01 Methods and reagents relating to inflammation and apoptosis

Publications (1)

Publication Number Publication Date
BR0313151A true BR0313151A (pt) 2007-07-17

Family

ID=31495819

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0313151-3A BR0313151A (pt) 2002-08-01 2003-08-01 métodos e reagentes que se relacionam à inflamação e à apoptose

Country Status (10)

Country Link
US (1) US20060078944A1 (pt)
EP (1) EP1542722A4 (pt)
JP (1) JP2006509724A (pt)
CN (1) CN1700930A (pt)
AU (1) AU2003258036A1 (pt)
BR (1) BR0313151A (pt)
CA (1) CA2494276A1 (pt)
IL (1) IL166633A0 (pt)
MX (1) MXPA05001268A (pt)
WO (1) WO2004012673A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003277828B2 (en) * 2002-10-29 2009-06-04 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
WO2005035746A2 (en) * 2003-10-02 2005-04-21 Xantos Biomedicine Ag Medical use of tbk-1 or of inhibitors thereof
JP2008528006A (ja) * 2005-01-28 2008-07-31 アポロ ライフ サイエンシズ リミテッド 分子およびそのキメラ分子
CN102803500B (zh) 2009-06-05 2014-11-19 13治疗有限公司 免疫调节肽和使用方法
RU2571489C2 (ru) 2009-10-26 2015-12-20 Нестек С.А. Способы выявления препаратов и аутоантител против tnf
BR112013009376A2 (pt) 2010-10-18 2016-07-26 Nestec Sa métodos para determinar isótipos de anticorpos antifármacos
CN102776264B (zh) * 2011-05-07 2016-09-07 姜石松 与凋亡或坏死相关的TNFα短肽及其应用
MX343324B (es) 2011-07-06 2016-11-01 Nestec Sa Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
BR112017011545A2 (pt) 2014-12-05 2018-03-13 Nestec Sa ensaio de desvio de mobilidade homogênea indireto para a detecção de produtos biológicos nas amostras do paciente
CN104987380B (zh) * 2015-06-02 2018-05-18 上海英邈生物科技有限公司 一种检测血浆炎性细胞因子自身抗体的组合物、试剂盒与方法
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106271A (en) * 1992-09-03 2008-03-20 Yeda Res & Dev Ligand to TNF 75P receptor and its preparation
DE4006269A1 (de) * 1990-02-28 1991-08-29 Max Planck Gesellschaft Antikoerper gegen den tumor-nekrosefaktor-rezeptor
ZA966663B (en) * 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
US5837514A (en) * 1997-03-07 1998-11-17 Tularik Inc. IκB kinases
US6365366B1 (en) * 2000-03-13 2002-04-02 Tularik Inc. T2k kinase assays

Also Published As

Publication number Publication date
CA2494276A1 (en) 2004-02-12
WO2004012673A2 (en) 2004-02-12
CN1700930A (zh) 2005-11-23
JP2006509724A (ja) 2006-03-23
IL166633A0 (en) 2006-01-15
EP1542722A4 (en) 2006-02-01
AU2003258036A1 (en) 2004-02-23
EP1542722A2 (en) 2005-06-22
WO2004012673A3 (en) 2004-07-15
US20060078944A1 (en) 2006-04-13
MXPA05001268A (es) 2005-10-06

Similar Documents

Publication Publication Date Title
Ruhl et al. Soluble collagen VI drives serum-starved fibroblasts through S phase and prevents apoptosis via down-regulation of Bax
Koutras et al. The upgraded role of HER3 and HER4 receptors in breast cancer
BR0313151A (pt) métodos e reagentes que se relacionam à inflamação e à apoptose
EP2387717B1 (en) Methods of determining patient response by measurement of her-2 expression
WO2009067546A3 (en) Lung cancer markers and uses thereof
CL2008003527A1 (es) Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7
BRPI0513189A (pt) métodos e composições para a detecção de doenças ovariana
TW200513469A (en) Antibodies against insulin-like growth factor I receptor (IGF-IR) and uses thereof
Meirson et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors
WO2004094647A3 (en) Methods of treating diseases responsive to induction of apoptosis and screening assays
AR026946A1 (es) Osteoprotegerina/receptores de factores de necrosis de tumores
CN103356636A (zh) Theramutein调节剂
Veine et al. A D-amino acid containing peptide as a potent, noncovalent inhibitor of α5β1 integrin in human prostate cancer invasion and lung colonization
CN105264382A (zh) 基于检测her3活化辅助癌症的诊断、预后和治疗的系统和方法
JP6626037B2 (ja) 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法
US20130216523A1 (en) Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression
Bosse et al. Mass spectrometry‐based secretome analysis of non‐small cell lung cancer cell lines
Jun et al. Expression of MET in alveolar soft part sarcoma
AR048840A1 (es) Epitopes inductores de la muerte de las celulas t
WO2003105773A3 (en) MUTATIONS OF PDGFRA ACTIVATED AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS
BRPI0607016A2 (pt) marcadores polipeptìdicos para o diagnóstico de cáncer de próstata
Bußmann et al. Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets
BR0116763A (pt) Anticorpos humanos especìficos para terapia seletiva do c ncer
WO2005107803A2 (en) Methods of determining the prognosis and treatment of subjects with lung cancer
US9470693B2 (en) Method for quantifying proteins and isoforms thereof

Legal Events

Date Code Title Description
B10A Cessation: cessation confirmed

Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, SOLICITADA ATRAVES DA PETICAO NO 20090076917/RJ DE 11.08.2009.